Supplementary Table S18 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
收藏NIAID Data Ecosystem2026-05-02 收录
数据链接：
官方服务：
资源简介：
Supplementary Table S18. Half maximum inhibitory concentrations (IC50) for cisplatin, paclitaxel and olaparib in cell lines after CRISPR/Cas-9 mediated RB1 knockout.
创建时间：
2024-08-15
